Premium
The effects of cyclophosphamide, ketoconazole, aclacinomycin‐A, methotrexate, and scheduled methotrexate‐5‐fluorouracil combination chemotherapy on the transplantable R‐3327 prostatic adenocarcinoma in the F 1 hybrid male rat
Author(s) -
Smith James B.,
Ghayad Pierre Y.,
Dhabuwala C. B.,
Drelichman Anibal,
Pierce James M.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19850901)56:5<1045::aid-cncr2820560513>3.0.co;2-b
Subject(s) - methotrexate , medicine , ketoconazole , cyclophosphamide , chemotherapy , fluorouracil , adenocarcinoma , pharmacology , urology , cancer , dermatology , antifungal
Male F 1 hybrid rats bearing the R‐3327 transplantable prostatic adenocarcinoma demonstrating similar growth patterns within the original sample of animals were carefully separated into control and treatment groups. This assured treatment of tumors with similar cell kinetics within each group. In the first study, two separate drug protocols were investigated by intraperitoneal injection, namely cyclophosphamide (100 mg/kg) once every 4 weeks for 8 weeks and scheduled methotrexate (7.5 mg/kg) followed in 90 minutes by 5‐fluorouracil (50 mg/kg) once each week for 8 weeks. Excellent suppression of tumor growth was obtained with each treatment protocol. Both were significant at the 0.01 level. In the second study, methotrexate (100 mg/kg) intraperitoneally once each week for 6 weeks, aclacinomycin‐A intraperitoneally once each week for 4 weeks, and ketoconazole (60 mg/kg) via gavage 5 times a week for 6 weeks were administered to the animals in each respective group. Aclacinomycin‐A and ketoconazole showed significant suppression of tumor growth at the 0.01 and 0.05 levels, respectively. Methotrexate suppressed tumor growth, but did not reach levels of significance over the duration of the study (0.2 < P < 0.3).